Shenwan Hongyuan keeps HKD 30.40 target for 3SBio stock

Published on 10/15/2026 at 20:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached RMB 4.53 billion in the first half of 2026, up 3.90 percent. 3SBio stock costs EUR 1.63 on October 15, 2026.

Target and interim revenue

Shenwan Hongyuan maintained a HKD 30.40 target on September 19, 2026.
First-half 2026 revenue reached RMB 4.53 billion, up 3.90 percent year over year.
3SBio stock costs EUR 1.63 at Lang & Schwarz on October 15, 2026 at 8:11 p.m. CEST.
3SBio carried a P/E ratio of 3.70 on October 15, 2026.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio (KYG8875G1029) remains under a HKD 30.40 price target from Shenwan Hongyuan, which maintained its Buy rating in a report dated September 19, 2026, as reported by The Globe and Mail. 3SBio was trading at EUR 1.63 at Lang & Schwarz on October 15, 2026 at 8:11 p.m. CEST, in after-hours trading.

Revenue growth came with profit pressure

For the six months ended June 30, 2026, revenue rose 3.90 percent year over year to RMB 4.53 billion, while net income declined 15.60 percent to RMB 1.15 billion. Simply Wall St also reported adjusted earnings per share of CN¥0.45, down from CN¥0.57 in the first half of 2025, and a profit margin of 25.00 percent versus 31.00 percent a year earlier.

The contrast matters for valuation. Revenue expanded, but the lower headline profit and margin leave the market focused on operating costs and the conversion of pipeline activity into earnings.

Price position after the Hong Kong close

On HKEX, 3SBio last stood at HKD 14.36 on October 15, 2026 at 4:08 p.m. HKT, with the session closed. The analyst target therefore sits well above the home-market quotation, while the euro quotation remained at EUR 1.63 during the German after-hours phase.

On September 29, 2026, 3SBio had secured China commercialization rights for MindRank AI's oral GLP-1 candidate MDR-001, according to Simply Wall St. The agreement gives 3SBio a potential entry into the obesity-treatment market, but development and regulatory execution remain material factors.

Valuation and peer comparison

3SBio had a P/E ratio of 3.70 and a market capitalization of HKD 35.9 billion on October 15, 2026. CSPC Pharmaceutical Group traded at a P/E of 11.63 with a market capitalization of HKD 101.1 billion, while Sino Biopharmaceutical carried a P/E of 33.99 and a market capitalization of HKD 93.9 billion.

Comparison with peers

3SBio: P/E 3.70, market capitalization HKD 35.9 billion

CSPC Pharmaceutical Group (HKEX, HKD): plus 0.62 percent, P/E 11.63, market capitalization HKD 101.1 billion

Sino Biopharmaceutical (HKEX, HKD): plus 2.03 percent, P/E 33.99, market capitalization HKD 93.9 billion

Price and investor perspective

The target, interim earnings mix and valuation gap leave three distinct reference points for investors: the analyst view, the latest profit trend and the comparison with larger Hong Kong peers.

The further course of trading is shown by the continuously updated real-time quote of 3SBio stock.